Only one large western pharmaceutical company will be run by a scientist following completion of the current round of acquisitions, in spite of the growing need for strengthened innovation to develop new medicines.

Only John Lechleiter, appointed chief executive of Eli Lilly of the US a year ago, has an academic science background, although Daniel Vasella, the chief executive who has run Novartis of Switzerland for the past decade, trained as a doctor.